JB Pharma continues winning streak with focus on chronic therapies
New Delhi: One of India’s fastest-growing pharma companies, JB Pharma which is continuing to be upbeat in market growth rates, has a clear roadmap as they are continuing to pivot a position in the chronic therapy space. Focusing particularly on cardiac care and hypertension. Further, to make an impeccable presence in the respiratory, paediatric, and probiotics segments, the company will work on these segments as they are evolving rapidly.
Detailing the growth strategies and the steady rise in niche segments, Dilip Singh Rathore, President-India Business, JB Pharma, said, “When KKR (private equity firm) took over we had a very focused approach and worked on our strengths. Specifically, cardio, gastro, dental, and kidney care Cilacar was upgraded to Cilacar T, which became the major growth driver for us. Nicardia was upgraded to Nicardia XL, Metrogyl became Metrogyl ER and we made sure that the big brands became bigger.”
Reminiscing about the focused approach, Rathore said, “As a company, we were traditionally very weak at launching new products, and our new product contribution was less than one per cent. However, we endured the challenge and started developing the life cycle of new brands. We developed two new divisions, respiratory and paediatric segments, and started to get almost 3 to 4 per cent of the market in terms of our share, which helped us in our growth.”
Narrating that the prevalence of cardio or cardiometabolic diseases is increasing multi-fold and it is the fastest-growing market, almost six to seven per cent, Rathore informed that in terms of product and business, almost 48 per cent contribution was coming from chronic therapy, and the endeavour is to reach 60 per cent.
“We want 60 per cent of our contribution to be towards chronic therapy. At the same time, we’ll continue to innovate in terms of launching new life cycle management products.”
Elucidating further, Rathore informed that JB Pharma has grown 22 per cent in the cardiology segment. He said, “Cilnidipine or Cilacar T can be the second largest brand apart from Telmisartan. So, our footprint is very strong in this entire segment, and we will continue to do more in the segment.”
“More and more pharma companies are focused on the chronic segment; it is growing by 10 to 11 per cent and there are four to five major pharma players in the industry in the chronic segment. We became the third-largest player in the hypertension market. We will continue to make acquisitions in the entire chronic therapy space. We will increase our reach in the hypertension space, as there is a gap in accessibility. Cilacar, the brand is valued at Rs 580 crore and we are looking to increase it to Rs 1000 crore in three to four years.”
As JB Pharma is set to complete 50 years in 2025, Rathore intimated that the goal for the golden jubilee is to accelerate the growth of the top brands of the company. He concluded, “Apart from the cardiac space, we have good potential in respiratory, gastroenterology, nephrology, dentistry, and paediatrics. The paediatric segment has 10 per cent of the market share and is the third largest. We would continue to have a focused approach as we did in the last five years and work on augmenting these segments in the next two to three years.”
Source – ETHealth World
